Tipifarnib

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma

Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

Expanded Access to Tipifarnib

Tipifarnib in Advanced Squamous NSCLC With Oncogen HRAS MutAtionS

Tipifarnib in Subjects With Myelodysplastic Syndromes

Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid Leukemia

Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations

Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Responded to Standard Therapy

Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy

Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission

Cardiovascular Safety Study of Tipifarnib in Patients With Advanced Solid Malignancies

Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer

Study of Tipifarnib in Patients With Previously-Treated, Advanced, HRAS Mutant Urothelial Carcinoma

Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer

Combination Chemotherapy Plus Radiation Therapy With or Without Tipifarnib in Treating Patients With Locally Advanced Pancreatic Cancer

Tipifarnib and Radiation Therapy in Treating Patients With Unresectable Locally Advanced Pancreatic Cancer

Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma

R115777 in Treating Patients With Refractory or Recurrent Acute Leukemia or Chronic Myelogenous Leukemia